Biofrontera AG (NASDAQ:BFRA) has scheduled a conference call for 27th August 2020 at 4:00 AM Eastern Time to announce its 2Q20 financial results.
The company disclosed financial results after close of U.S. markets on Wednesday 26th August 2020
The conference call will also be webcast live under the investor relations section of the website www.biofrontera.com/en/investors/financial-calendar
To participate on the live call, please dial +49 69201744220 Toll Free, with passcode : 43177738#
Earnings Expectation
Biofrontera AG is reporting second quarter earnings results on Wednesday 26th August 2020, before market open. The consensus estimates from Thomson Reuters are loss of $ 0.16 per share from $ 7.90 million in revenue. For the full year, analysts predict revenues of $ 26.70 million, while looking forward to loss of $ 1.09 per share.
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
